LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Equities researchers at First Analysis increased their Q1 2018 EPS estimates for LeMaitre Vascular in a note issued to investors on Tuesday. First Analysis analyst now expects that the medical instruments supplier will post earnings of $0.20 per share for the quarter, up from their prior forecast of $0.19. First Analysis has a “Equal Weight” rating and a $34.00 price objective on the stock. First Analysis also issued estimates for LeMaitre Vascular’s Q2 2018 earnings at $0.22 EPS, Q3 2018 earnings at $0.21 EPS and FY2018 earnings at $0.88 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The company had revenue of $24.80 million during the quarter, compared to analyst estimates of $25.49 million. During the same period in the prior year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was up 6.9% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/lemaitre-vascular-inc-expected-to-post-q1-2018-earnings-of-0-20-per-share-lmat.html.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday. Stifel Nicolaus restated a “buy” rating on shares of LeMaitre Vascular in a report on Sunday. Canaccord Genuity reduced their target price on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating on the stock in a report on Friday, October 27th. Benchmark Co. cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Finally, BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $32.20.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 7th. Stockholders of record on Wednesday, November 22nd will be issued a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 28.57%.

LeMaitre Vascular announced that its board has approved a stock buyback plan on Thursday, July 27th that permits the company to repurchase $7.50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 1.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

In other news, Director Lawrence J. Jasinski sold 2,030 shares of LeMaitre Vascular stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $34.23, for a total transaction of $69,486.90. Following the transaction, the director now owns 8,333 shares in the company, valued at approximately $285,238.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David B. Roberts sold 48,317 shares of LeMaitre Vascular stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $33.12, for a total value of $1,600,259.04. Following the transaction, the insider now owns 30,105 shares in the company, valued at approximately $997,077.60. The disclosure for this sale can be found here. Insiders have sold a total of 285,854 shares of company stock worth $9,851,441 in the last quarter. 23.70% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in shares of LeMaitre Vascular by 4.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after purchasing an additional 40,767 shares in the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 51.2% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 854,644 shares of the medical instruments supplier’s stock valued at $31,981,000 after purchasing an additional 289,575 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of LeMaitre Vascular by 23.5% during the 2nd quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after purchasing an additional 155,249 shares in the last quarter. State Street Corp lifted its holdings in shares of LeMaitre Vascular by 25.2% during the 2nd quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after purchasing an additional 77,009 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. lifted its holdings in shares of LeMaitre Vascular by 1.8% during the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock valued at $11,425,000 after purchasing an additional 6,638 shares in the last quarter. Institutional investors and hedge funds own 68.29% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.